Dimethaid WF10 fails Phase III for HIV
This article was originally published in Pharmaceutical Approvals Monthly
Dimethaid is halting development of its HIV/AIDS agent WF10 following the immune regulator's failure to meet primary endpoints in a 96-week, placebo-controlled, double-blind Phase III trial. Results from the North American trial's 229 late-stage AIDS patients "indicated no statistical difference between WF10 and placebo in affecting the time to onset of clinical progression, defined as any new AIDS-defining event or death," the firm says July 14. Dimethaid plans to evaluate the study's secondary results and "re-evaluate WF10's future business potential and its position in the company's long-term development pipeline." The firm notes WF10 (tetrachlorodecaoxygen) may have potential in autoimmune diseases and oncology...
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.